3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
37
Lung Neoplasms
20
Carcinoma, Hepatocellular
18
Breast Neoplasms
16
Small Cell Lung Carcinoma
14
Urinary Bladder Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
7
Liver Neoplasms
7
Neoplasm Metastasis
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Ovarian Neoplasms
5
Neoplasms
5
Endometrial Neoplasms
5
Carcinoma, Transitional Cell
5
Carcinoma, Renal Cell
5
Carcinoma
5
Biliary Tract Neoplasms
5
Stomach Neoplasms
4
Melanoma
4
Colorectal Neoplasms
4
Cholangiocarcinoma
4
Prostatic Neoplasms
3
Neoplasms by Site
3
Esophageal Neoplasms
3
Carcinoma, Squamous Cell
3
Uterine Cervical Neoplasms
2
Turcot syndrome
2
Thyroid Neoplasms
2
Thoracic Neoplasms
2
Interventions
X-Rays
4
Phantoms, Imaging
4
Nuclear Medicine Department, Hospital
4
Magnetic Resonance Spectroscopy
4
regorafenib
3
Specimen Handling
3
Nivolumab
3
Cyclophosphamide
3
Biopsy
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
pembrolizumab
2
olaparib
2
larotrectinib
2
ivosidenib
2
fludarabine
2
ensartinib
2
cabozantinib
2
Etoposide
2
Docetaxel
2
tocilizumab
1
tazemetostat
1
poly ICLC
1
palbociclib
1
naxitamab
1
mifamurtide
1
humanized 3F8 anti-GD2 monoclonal antibody
1
glucarpidase
1
gamma-Glutamyl Hydrolase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Osteosarcoma
×
durvalumab
×
Clear all
NCT04668300
2026-04-15
DOSa
M.D. Anderson Cancer Center
Phase 2
Active not recruiting
75 enrolled